Join Matthew Blandford, Sedulo Group's VP of Business Development in New Jersey for Pharma CI! 💡 Learn how your peers navigate the constantly changing CI landscape and gain valuable benchmarks and insights to enhance your CI strategies. 🔍 You’ll see data gathered from 109 survey responses across 90 life sciences companies. This comprehensive survey analyzes competitive intelligence (CI) practices, challenges, and trends within the life sciences sector. Here is what you can expect: · Explore CI Practices and Trends · Benchmarking CI Structures and Approaches · Understand Peer Challenges and Solutions · Discover Vendor Vetting and Engagement Strategies · Uncover Future Perspectives on Life Sciences #pharmaci2024 #CompetitiveIntelligence #LifeSciences
Sedulo Group’s Post
More Relevant Posts
-
Can't believe it's already less than a week until Pharma Market Research Conference PMRC 2024! Really excited to see all the great research ideas and case studies, and doubly excited to have the chance to partner with two fantastic co-presenters to talk about some of our recent work using social media listening to inform clinical trial design/recruitment with a global lens. Looking forward to seeing you there! #marketresearch
-
-
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
2024 life sciences industry outlook
rsmbuzz.com
-
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
2024 life sciences industry outlook
rsmbuzz.com
-
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
2024 life sciences industry outlook
rsmbuzz.com
-
Great to see this in print! Axian supported BMS (Jeremy Jokinen, Sibel Guerler) in bringing together experts in #behaviouralscience (Joanne Treacy Elaine H Morrato, DrPH MPH, Rob Horne Michael Wolf Mark Lightowler PhD, GFMD Ameet Bakhai) to explore how learnings from the field could help improve pharma #riskmanagement. Hoping that this work sparks a conversation in how we can move beyond a focus on information provision.
-
-
Pharmaceutical leaders are attempting to navigate challenges by changing the way they invest in access data, solutions, and strategy. To properly understand the challenges pharma companies face, it’s critical to understand the ins and outs of the most pressing patient access issues.
Payer revenue optimization tactics are widening the gross-to-net bubble for pharma companies. https://ow.ly/qYRY50SzMxt In Life Science Leader, MMIT's Dinesh Kannan Kabaleeswaran and Jennifer (Goldenberg) Klarer, M.Sc.Eng., partner at The Dedham Group, discusses how pharma is shifting to early-stage market access planning in response. Click the link to check out the insights!
-
-
Some insights into the upcoming life sciences industry and market
A Look Ahead in Life Sciences: What We Are Tracking in the Third Quarter of 2024 and Beyond | Insights & Resources | Goodwin
goodwinlaw.com
-
Hotel-ownership executives took the stage at the 20th annual Pharma Forum conference for life-science meeting professionals to give the audience some of the ugly details about why event pricing is so different from the pre-pandemic environment—and why today’s rates are not a temporary blip but rather a new foundation for future prices. #meetingprofs #eventprofs https://buff.ly/3xjl3a5
Planners Get Straight Talk from Hotel Owners
-
Dive into the future of healthcare with DelveInsight Business Research LLP! 🚀 Our latest report forecasts significant growth in the Malignant Ascites Market by 2034, offering insights into emerging trends and key players. Lindis Biotech GmbH, Wuhan YZY Biopharma Co. Ltd., AstraZeneca plc, Baxter International Inc., BD and Company, F. Hoffmann-La Roche Ltd, Merit Medical Systems, Inc., Neovii Pharmaceuticals AG, Pfizer, Inc., Novartis AG, GI Supply, Roche and others are leading the charge in developing innovative therapies to tackle this challenging condition. With a projected market size set to soar from USD 1,990 million in 2020 to USD 2,340 million by 2034, the opportunities are immense. Discover the latest treatment practices, upcoming drugs like Catumaxomab and M 701, and groundbreaking research initiatives like the Phase II study by Wuhan YZY Biopharma Co., Ltd. Together, we're revolutionizing care for patients with Malignant Ascites. Contact us for a free sample report and join the journey towards a brighter, healthier future @ https://lnkd.in/gjRbe2BR #MalignantAscites #HealthcareInnovation #FutureOfMedicine #healthcare #biotechnology #lifesciences #pharmaceuticalindustry #pharmaceutical #marketresearch #marketforecast #markettrends #consulting #healthcareconsulting #consultingservices #marketforecast
Sample page for Malignant Ascites
delveinsight.com
